ArticleClinical practice (London, England)2012
Use of medical foods and nutritional approaches in the treatment of Alzheimer's disease.
Article in Clinical practice (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 69 citations in OpenAlex.
- Drug-food Interactions in the Era of Molecular Big Data, Machine Intelligence, and Personalized Health.Recent advances in food, nutrition & agriculture · 2022Review
- Advances on Therapeutic Strategies for Alzheimer's Disease: From Medicinal Plant to Nanotechnology.Molecules (Basel, Switzerland) · 2022Review
- A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer's Disease.Frontiers in aging neuroscience · 2022Article
- Identification of new BACE1 inhibitors for treating Alzheimer's disease.Journal of molecular modeling · 2021Article
- The Impact of Nutrients on Mental Health and Well-Being: Insights From the Literature.Frontiers in nutrition · 2021Review
- Administration ofFrontiers in aging neuroscience · 2021Article
- Nootropic Effects ofBioMed research international · 2020Article
- Mediterranean and MIND Diets Containing Olive Biophenols Reduces the Prevalence of Alzheimer's Disease.International journal of molecular sciences · 2019Review
- Consolidated Biochemical Profile of Subacute Stage Traumatic Brain Injury in Early Development.Frontiers in neuroscience · 2019Article
- Review
- A Bacterial Component to Alzheimer's-Type Dementia Seen via a Systems Biology Approach that Links Iron Dysregulation and Inflammagen Shedding to Disease.Journal of Alzheimer's disease : JAD · 2016Review
- Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer's disease: a prospective, open-label pilot study.Clinical interventions in aging · 2016Observational
- Alzheimer's Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome.Current neuropharmacology · 2016Review
- [Vitamins and nutritional supplements in older persons: How to diagnose and when to substitute?].Der Internist · 2015Review
- Natural products and supplements for geriatric depression and cognitive disorders: an evaluation of the research.Current psychiatry reports · 2014Review
- Nutrition and prevention of Alzheimer's dementia.Frontiers in aging neuroscience · 2014Review
- The role of iron-induced fibrin in the pathogenesis of Alzheimer's disease and the protective role of magnesium.Frontiers in human neuroscience · 2013Review
- Alzheimer's disease clinical and research update for health care practitioners.Journal of aging research · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Alzheimer's disease, the most common cause of dementia, has a high global economic impact. To date, there is no curative treatment; therefore, many efforts are directed not only at novel potential disease-modifying treatments and interventions, but also to develop alternative symptomatic and supportive treatments. Examples of these efforts include the medical foods. There are three medical foods that claim to offer symptomatic benefits: Axona(®), Souvenaid(®) and CerefolinNAC(®). Axona supplies ketone bodies as alternative energy source to neurons. Souvenaid provides precursors thought to enhance synaptic function. CerefolinNAC addresses the role of oxidative stress related to memory loss. The current scientific evidence on these medical foods is reviewed in this article. Furthermore, we also review the concept and evidence supporting use of the Mediterranean diet, a possible alternative to medical foods that, if implemented correctly, may have lower costs, fewer side effects and stronger epidemiological health outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.